- Home
- TSHA vs PACB Comparison
TSHA vs PACB Comparison
Compare TSHA & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | PACB |
|---|---|---|
| Founded | 2019 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 715.5M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TSHA | PACB |
|---|---|---|
| Price | $5.52 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $10.22 | $2.08 |
| AVG Volume (30 Days) | 3.6M | ★ 6.3M |
| Earning Date | 11-04-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,310,000.00 | ★ $154,584,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $11.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $0.85 |
| 52 Week High | $6.02 | $2.73 |
Technical Indicators
Market Signals| Indicator | TSHA | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 45.20 |
| Support Level | $5.58 | $1.67 |
| Resistance Level | $6.02 | $1.89 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 23.08 | 25.12 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.